STOCK TITAN

ALPS Group (ALPS) Stock Price, News & Analysis

ALPS NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
53 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+33.4% close of August 26, 2026
1-year change
-66.9% closing prices, November 13, 2025 to November 13, 2026
1-month change
-32.6% closing prices, October 13, 2026 to November 13, 2026

Company Description

ALPS Group Inc (NASDAQ: ALPS) is described in recent company communications as a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine. The company is the parent of Alps Life Sciences Inc., which is characterized as an integrated biotechnology platform that brings together research and development, medical services, and wellness solutions of advanced therapies within a unified ecosystem. According to its stated mission, ALPS Group aims to promote a fair healthcare ecosystem by improving accessibility and affordability of advanced healthcare.

Following the completion of a business combination with Globalink Investment Inc., a special purpose acquisition company, ALPS Group Inc became the surviving publicly traded entity and its ordinary shares trade on the Nasdaq Stock Market under the ticker symbol ALPS. After this transaction, the company’s headquarters is described as being located in Kuala Lumpur, Malaysia. The business combination structure involved a redomestication merger and an acquisition merger, resulting in Alps Life Sciences Inc becoming a wholly owned subsidiary of ALPS Group Inc.

Business focus and platform

Based on the company’s own description, ALPS Group Inc focuses on building an integrated biotechnology and healthcare platform. Its activities are presented as integrating:

  • Biotechnology research and development
  • Medical services related to advanced therapies
  • Wellness solutions aligned with predictive, preventive, and precision medicine

The company’s stated objective is to improve healthcare outcomes globally by advancing predictive, preventive, and precision medicine and by working toward accessibility and affordability of such care. The platform is positioned as unifying scientific research, clinical applications, and wellness-oriented offerings under one ecosystem.

Corporate structure and background

ALPS Group Inc is identified as the parent company of Alps Life Sciences Inc. In connection with its listing on Nasdaq, ALPS Group Inc completed a business combination with Globalink Investment Inc, a Delaware-incorporated special purpose acquisition company. The transaction documentation referenced an amended and restated merger agreement and a two-step merger process, including a redomestication merger and an acquisition merger, after which Alps Life Sciences Inc became a wholly owned subsidiary of ALPS Group Inc.

The company has also disclosed a private investment in public equity (PIPE) subscription with certain investors in connection with the business combination, intended to support its growth strategy and working capital needs. These details underscore that ALPS Group Inc emerged as a publicly traded biotechnology and healthcare platform through a SPAC business combination route.

Geographic and listing context

In its public announcements, ALPS Group Inc notes that its headquarters will be located in Kuala Lumpur, Malaysia following the closing of the business combination. The company’s ordinary shares are stated to trade on the Nasdaq Stock Market under the symbol ALPS, while its warrants are described as trading on the over-the-counter market under a separate symbol. The company also frames its ambitions in terms of contributing to biotechnology development and healthcare accessibility on a global scale.

Stated mission and healthcare orientation

ALPS Group Inc’s mission statements emphasize creating what it calls a fair healthcare ecosystem. This involves advancing predictive, preventive, and precision medicine and focusing on making advanced therapies more accessible and affordable. The company’s communications reference genomics, mRNA and personalized vaccines, and cellular therapies in the context of its broader mission to improve healthcare outcomes, though detailed product-level descriptions are not provided in the available materials.

Within this framework, ALPS Group Inc presents itself as uniting science, technology, and healthcare practice in a single platform, with an emphasis on advanced therapies and personalized approaches to medicine. The company also references initiatives intended to support a biotechnology ecosystem, such as the development of a biotechnology hub concept, as part of its broader narrative about contributing to healthcare innovation and collaboration.

Management and governance developments

In its public disclosures, ALPS Group Inc has highlighted changes in its leadership team. The company announced the appointment of a Chief Financial Officer responsible for financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury functions for ALPS Group and its subsidiaries. The company also notes that, upon completion of the business combination, the executive officers of Alps Life Sciences Inc immediately prior to closing became the initial executive officers of ALPS Group Inc, with its chief executive officer also serving as chairman of the board of directors.

These disclosures indicate a focus on establishing a governance and financial framework to support the company’s stated growth plans and its role as a publicly traded biotechnology and healthcare platform.

Relationship to former ALPS-ticker energy company

The ticker symbol ALPS was previously associated in news reports with Alpine Summit Energy Partners, Inc., a U.S.-based company that operated and developed oil and gas assets. That company announced a voluntary Chapter 11 process in the U.S. Bankruptcy Court for the Southern District of Texas and described itself as operating and developing oil and gas assets. Those historical disclosures relate to a different business profile and corporate entity than ALPS Group Inc’s current description as an integrated biotechnology research and healthcare platform. Users researching the symbol ALPS may therefore encounter both the historical energy company context and the more recent biotechnology and healthcare platform associated with ALPS Group Inc.

Investor considerations

Public information about ALPS Group Inc emphasizes its identity as a biotechnology and healthcare platform, its Nasdaq listing under the symbol ALPS, its headquarters location in Kuala Lumpur, Malaysia, and its role as the parent of Alps Life Sciences Inc. Investors and observers examining this company may wish to review its public filings and press releases for more detailed information about its operations, risk factors, and corporate structure, while also recognizing the historical use of the ALPS ticker by Alpine Summit Energy Partners, Inc. in the oil and gas sector.

Stock Performance

$1.18
+0.43%
+0.00
Last updated: November 13, 2026 at 16:00
-66.9%
Performance 1 year
$37.4M

ALPS Group (ALPS) closed at $1.18 on November 13, 2026. Over the past 12 months, the price has lost 66.9%.

See what a $1,000 investment in ALPS would be worth today

Average down calculator for ALPS

ALPS Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

ALPS Group has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, management, clinical trial. View all ALPS news →

Financial Highlights

ALPS Group generated $4.9M in revenue in FY2026, retaining a 32.1% gross margin, operating income reached -$2.0M (-41.8% operating margin), and net income was -$2.0M, reflecting a -41.4% net profit margin. Diluted earnings per share stood at -$0.02. The company generated -$2.6M in operating cash flow. The current ratio was 0.36, measuring current assets divided by current liabilities.

$4.9M
Revenue (FY2026)
-$2.0M
Net Income (FY2026)
-$2.6M
Operating Cash Flow

Upcoming Events

MAY
10
May 10, 2027 Regulatory

Potential extension deadline

Potential additional 180-day extension (if granted) would extend compliance deadline; still risks delisting if not cured.

ALPS Group has 1 upcoming scheduled event. The next event, "Potential extension deadline", is scheduled for May 10, 2027 (in 176 days). Investors can track these dates to stay informed about potential catalysts that may affect the ALPS stock price.

Short Interest History

Last 12 Months

Short interest in ALPS Group (ALPS) currently stands at 82.5 thousand shares, down 30.6% from the previous reporting period, representing 0.2% of the float.

Days to Cover History

Last 12 Months

Days to cover for ALPS Group (ALPS) currently stands at 2.9 days, down 28.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 194%. Across the settlements charted above, it has ranged from 1.0 to 4.1 days.

Frequently Asked Questions

The current stock price of ALPS Group (ALPS) is $1.18 as of November 13, 2026.

The market cap of ALPS Group (ALPS) is approximately $37.4M. Learn more about what market capitalization means .

The FY2026 revenue of ALPS Group (ALPS) is $4.9M, from its most recent completed fiscal year.

The FY2026 net income of ALPS Group (ALPS) is -$2.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of ALPS Group (ALPS) is -$0.02 for FY2026, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of ALPS Group (ALPS) is -$2.6M for FY2026, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of ALPS Group (ALPS) is -41.4% for FY2026, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of ALPS Group (ALPS) is -41.8% for FY2026, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of ALPS Group (ALPS) is 32.1% for FY2026, its most recent completed fiscal year. Learn about gross margins.

The current ratio of ALPS Group (ALPS), current assets divided by current liabilities, was 0.36 at the end of FY2026, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of ALPS Group (ALPS) is $1.6M for FY2026, its most recent completed fiscal year.

The operating income of ALPS Group (ALPS) is -$2.0M for FY2026, its most recent completed fiscal year. Learn about operating income.

According to its public communications, ALPS Group Inc is a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine. It is described as integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes.

ALPS Group Inc is identified as the parent company of Alps Life Sciences Inc. Alps Life Sciences Inc is described as an integrated biotechnology platform that combines research and development, medical services, and wellness solutions of advanced therapies, and it became a wholly owned subsidiary of ALPS Group Inc through the business combination with Globalink Investment Inc.

Following the completion of its business combination with Globalink Investment Inc, ALPS Group Inc’s ordinary shares are stated to trade on the Nasdaq Stock Market under the ticker symbol ALPS. The company has also indicated that its warrants trade on the over-the-counter market under a separate symbol.

In its announcement regarding the closing of the business combination with Globalink Investment Inc, ALPS Group Inc stated that, after the closing, the company’s headquarter will be located in Kuala Lumpur, Malaysia.

ALPS Group Inc describes its mission as promoting and creating a fair healthcare ecosystem by advancing predictive, preventive, and precision medicine, with the aim of improving accessibility and affordability of advanced healthcare and improving healthcare outcomes globally.

ALPS Group Inc became a publicly traded entity through a business combination with Globalink Investment Inc, a Delaware special purpose acquisition company. The transaction involved a redomestication merger and an acquisition merger, after which ALPS Group Inc continued as the surviving publicly traded entity and Alps Life Sciences Inc became its wholly owned subsidiary.

In its public descriptions, ALPS Group Inc highlights biotechnology research and development, medical services, and wellness solutions of advanced therapies, all integrated under one ecosystem. The company associates these activities with predictive, preventive, and precision medicine.

ALPS Group Inc has announced the appointment of a Chief Financial Officer responsible for financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury for ALPS Group and its subsidiaries. The company has also stated that the executive officers of Alps Life Sciences Inc immediately prior to the business combination became the initial executive officers of ALPS Group Inc, with its chief executive officer serving as chairman of the board.

ALPS Group Inc emphasizes predictive, preventive, and precision medicine in its healthcare approach. Its communications reference genomics, mRNA and personalized vaccines, and cellular therapies in the context of its mission to deliver advanced medical care and improve healthcare outcomes, while seeking greater accessibility and affordability.